StockNow
Calendar
Log in
U.S. Markets

Eli Lilly (LLY) and Hims & Hers Health (HIMS) announce an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron)

ORIGINAL · NewsquawkEli Lilly (LLY) and Hims & Hers Health (HIMS) announce an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron)
StockNow breaking-news AI analysis

Lilly and Hims & Hers announced an agreement to expand access to two named medicines, but the available item provides no further terms or details.

2 stocks
LLYEli Lilly & Co.$1,352.38Current priceHIMSHims & Hers Health, Inc.$25.86Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

The US and Iran are reportedly moving closer to a potential agreement to end the war, according to Bloomberg

Commodities

[MARKET UPDATE] Crude benchmarks dip as markets digest a Qatar Emir-US President Trump phone call; the broader risk tone stabilises with European equity futures pausing their downside

Geopolitics

Iranian lawmaker warns that Iran's response to America will include Europe, Tasnim reports; the response could lead to oil crossing the USD 150 mark